International Journal of Environmental Research and Public Health Article Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014 Karen Bissell 1,* , Philippa Ellwood 2, Eamon Ellwood 2 , Chen-Yuan Chiang 3,4, Guy B. Marks 5, Asma El Sony 6 , Innes Asher 2, Nils Billo 7, Christophe Perrin 8 and the Global Asthma Network Study Group † 1 School of Population Health, University of Auckland, Auckland 1023, New Zealand 2 Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland 1023, New Zealand;
[email protected] (P.E.);
[email protected] (E.E.);
[email protected] (I.A.) 3 Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan;
[email protected] 4 Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan 5 South Western Sydney Clinical School, University of New South Wales, Sydney 2085, Australia;
[email protected] 6 The Epidemiological Laboratory (Epi-Lab), for Public Health and Research, Khartoum, Sudan;
[email protected] 7 Independent Consultant, 80220 Joensuu, Finland;
[email protected] 8 Farmalex, 75008 Paris, France;
[email protected] * Correspondence:
[email protected]; Tel.: +64-9-373-7999 † Membership of the Global Asthma Network Study Group is provided in the Acknowledgements. Received: 28 December 2018; Accepted: 2 February 2019; Published: 19 February 2019 Abstract: Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited.